Veru announces the presentation of positive phase 2 clinical data of enobosarm in ar+er+her2- metastatic breast cancer patients that have progressed on estrogen blocking agents and cdk 4/6 inhibitor at the esmo breast cancer congress 2021

Miami, may 05, 2021 (globe newswire) -- veru inc. (nasdaq: veru), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the clinical results from the phase 2 clinical study of enobosarm, an oral selective androgen receptor targeting agonist, in heavily pretreated women with ar+er+her2- advanced breast cancer including further efficacy data and an analysis of patients who have failed both estrogen blocking agents and cdk 4/6 inhibitors, will be presented at the european society for medical oncology (esmo) breast cancer virtual congress 2021 to be held may 05-08, 2021.
VERU Ratings Summary
VERU Quant Ranking